Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
What hotspot and heterogeneity metrics do you utilize when delivering PMRT to a patient who has had breast reconstruction?
How do you use 105%, 107% and max dose metrics differently compared with non-reconstructed cases?
Answer from: Radiation Oncologist at Community Practice
I try to follow the same as intact breast. Limiting hot spot < 110 and V 105 < 5-10% and not hot spot in IM fold. Patel et al., PMID 30145393
Sign in or Register to read more
22655
Related Questions
Do you test /back project various bolus such as mesh or superflab to verify dosimetry and which do you prefer? How do you have staff apply it consistently? eg mesh bolus for chest wall
For a young female (<40) with HR-/HER2+ cT1-2N1, ypT1aN0 s/p mastectomy with SLNB, would you offer PMRT?
What are your top takeaways from SABCS 2023?
In the setting of recurrent breast cancer localized to the chest wall (no prior RT), do you allow concurrent abemaciclib or Enhertu with post-operative comprehensive chest wall irradiation?
Under what circumstances would you pursue completion ALND in a patient with multiple positive sentinel nodes after breast-conserving surgery?
Would you consider once weekly radiation with a simultaneous integrated boost for a patient with node negative breast cancer with a positive margin for whom reexcision is not an option?
When do you consider the addition of concurrent pembrolizumab to breast irradiation?
Would you offer partial breast radiation for bilateral DCIS?
How would you approach an isolated supraclavicular nodal recurrence involving the skin in a patient who has received standard chest wall and nodal radiation therapy?
Would you offer a patient with “good-risk” DCIS and an elevated DCISionRT score APBI or WBI?